<—– Return to Fellows Directory


BSc (Hons), PhD (UNSW), AM, FASSA, FAHMS
,
Health Sciences
2002

Professor Wayne Hall is the Professor and Inaugural Director of the Centre for Youth Substance Abuse Research at the University of Queensland. He also has visiting Professorial appointments at the National Addiction Centre, Kings College London; the National Drug and Alcohol Research Centre, UNSW, and the London School of Hygiene and Tropical Medicine. He is researching the public policy implications of the legalisation of cannabis for medical and recreational use and the public health effects of e-cigarettes. :

He was formerly an NHMRC Australia Fellow and Professorial Research Fellow at the University of Queensland Centre for Clinical Research (2010-2013), Professor of Public Health Policy in the School of Population Health (2005-2009) and Director of the Office of Public Policy and Ethics at the Institute for Molecular Bioscience at UQ (2001-2005). He was Executive Director and Professor at the National Drug and Alcohol Research Centre at the University of New South Wales (1994-2001). He has also held appointments in the Medical Schools of Universities of Western Australia (1983-1986) and New South Wales (1986-1988) where he introduced the teaching of bioethics into the undergraduate medical curriculum. He has been an Adviser to the World Health Organization on: the health implications of cannabis use (1993-1996); drug substitution treatment (1995-6); the contribution of illicit drug use to the Global Burden of Disease (2000-2002); the ethics of risk management (2001), vaccines against drug addiction (2001) and neuroscience research on the addictions (2002). He is a Member of the WHO Expert Advisory Panel on Drug Dependence and Alcohol Problems. In 2003 he was identified by the Institute for Scientific Analysis, as a Highly Cited Author in social science general, comprising less than one half of one percent of all publishing researchers - in the last two decades See http://isihighlycited.com

  • Books

  • Carter A, Hall WD, Illes J, eds. Addiction neuroethics: The ethics of addiction neuroscience research and treatment. Amsterdam: Elsevier, 2012.
  • Teesson M, Hall WD, Proudfoot H, Degenhardt L. Addictions, 2nd edn. Hove: Psychology Press, 2012.
  • Carter A, Hall WD. Addiction neuroethics: The promises and perils of neuroscience research on addiction. Cambridge: Cambridge University Press, 2012.
  • Room R, Fischer B, Hall WD, Lenton S, Reuter P. Cannabis policy: Moving beyond stalemate. Oxford: Oxford University Press, 2010.
  • Hall WD, Pacula RL. Cannabis use and dependence: public health and public policy. Cambridge: Cambridge University Press, 2003.
  • Teesson M, Degenhardt L, Hall WD. Addictions. Hove: Psychology Press, 2002.

Papers

  • Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin J, Hall WD, Patton G. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction 2013; 108:124-33.
  • Meurk CS, Carter A, Hall WD, Lucke J. Public understandings of addiction: Where do neurobiological explanations fit? Neuroethics 2013; 10.1007/s12152-013-9180-1: February 15.
  • Bell S, Carter A, Mathews R, Gartner C, Lucke J, Hall WD. Views of addiction neuroscientists and clinicians on the clinical impact of a ‘brain disease model of addiction’. Neuroethics 2013; 10.1007/s12152-013-9177-9: January 19.
  • Bell S, Partridge B, Lucke J, Hall WD. Australian university students' attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics 2013; 6:197-205.
  • Carter A, Hall WD. Ethical implications of research on craving. Addictive Behaviors 2013; 38:1593-9.
  • Forlini C, Hall WD, Maxwell B, Outram SM, Reiner PB, Repantis D, Schermer M, Racine E. Navigating the enhancement landscape. Embo Reports 2013; 14:123-28.
  • Hall WD, Carter A. Advocates need to show compulsory treatment of opioid dependence is effective, safe and ethical. Bulletin of the World Health Organization 2013; 91:146-46.
  • Lai FY, Bruno R, Hall WD, Gartner C, Ort C, Kirkbride P, Prichard J, Thai PK, Carter S, Mueller JF. Profiles of illicit drug use during annual key holiday and control periods in Australia: wastewater analysis in an urban, a semi-rural and a vacation area. Addiction 2013; 108:556-65.
  • Morphett K, Lucke J, Gartner C, Carter A, Meurk C, Hall WD. Public attitudes toward the treatment of nicotine addiction. Nicotine & Tobacco Research 2013; 10.1093/ntr/ntt037: March 18.
  • Shand FL, Campbell G, Hall WD, Lintzeris N, Cohen M, Degenhardt L. Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. Medical Journal of Australia 2013; 198:80-81.
  • Sara G, Burgess P, Malhi GS, Whiteford H, Hall WD. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophrenia Research 2013; 10.1016/j.schres.2013.04.017:April 15.
  • Meltzer EC, Hall WD, Fins JJ. Error and bias in the evaluation of prescription opioid misuse: Should the FDA regulate clinical assessment tools? Pain Medicine 2013; 10.1111/pme.12099: April 19.
  • Hall WD, Carter A. Anticipating possible policy uses of addiction neuroscience research. Drugs: Education, Prevention, and Policy 2013; 20:249-57.
  • Ambermoon P, Carter A, Hall WD, Dissanayaka N, O'Sullivan J. Compulsive use of dopamine replacement therapy: A model for stimulant drug addiction? (For Debate). Addiction 2012; 107:241-47
  • Gartner C, Barendregt J, Wallace A, Hall WD. Would vaccination against nicotine be a cost-effective way to prevent smoking uptake in adolescents? Addiction 2012; 107:801-9.
  • Hall WD, Babor T, Edwards G, Laranjeira R, Marsden J, Miller P, Obot I, Petry N, Thamarangsi T, West R. Compulsory detention, forced detoxification and enforced labour are not ethically acceptable or effective ways to treat addiction (Editorial). Addiction 2012; 107:1891-93.
  • Hall WD, Prichard J, Kirkbride P, Bruno R, Thai P, Gartner C, Lai F, Ort C, Mueller J. An analysis of ethical issues in using wastewater analysis to monitor illicit drug use. Addiction 2012; 107:1767-73.
  • Lucke J, Hall WD. Under what conditions is it ethical to offer incentives to encourage drug-using women to use long-acting forms of contraception? (For Debate). Addiction 2012; 107:1036-41.
  • Mathews R, Hall WD, Carter A. Direct-to-consumer genetic testing for addiction susceptibility: A premature commercialisation of doubtful validity and value (For debate). Addiction 2012; 107:2069-74.
  • Bell S, Lucke JC, Hall WD. Lessons for enhancement from the history of cocaine and amphetamine use. American Journal of Bioethics - Neuroscience 2012; 3:24-29.
  • Partridge B, Lucke J, Hall WD. A comparison of attitudes toward cognitive enhancement and legalized doping in sport in a community sample of Australian adults. American Journal of Bioethics - Primary Research 2012; 3:81-86.
  • Partridge B, Lucke J, Hall WD. Public attitudes towards the acceptability of using drugs to treat depression and ADHD. Australian and New Zealand Journal of Psychiatry 2012; 46:958-65.
  • Sara G, Burgess P, Harris M, Malhi G, Whiteford H, Hall WD. Stimulant use disorders: Characteristics and comorbidity in an Australian population sample. Australian and New Zealand Journal of Psychiatry 2012; 46:1173-81.
  • Teesson M, Slade T, Swift W, Mills K, Memedovic S, Mewton L, Grove R, Newton N, Hall WD. Prevalence, correlates and comorbidity of DSM-IV Cannabis Use and Cannabis Use Disorders in Australia. Australian and New Zealand Journal of Psychiatry 2012; 46:1182-92.
  • Gartner C, Scollo M, Marquart L, Mathews R, Hall WD. Analysis of national data shows mixed evidence of hardening among Australian smokers. Australian and New Zealand Journal of Public Health 2012; 36:408-14.
  • Hall WD. Driving while under the influence of cannabis (Editorial). British Medical Journal 2012; 344:e595.
  • Calabria B, Swift W, Slade T, Hall WD, Copeland J. The perceived health risks of cannabis use in an Australian household survey. Drug and Alcohol Review 2012; 31:809-12.
  • Hall WD. What place, if any, does information on putative cardioprotective effects of moderate alcohol use have in safer drinking guidelines? (Commentary). Drug and Alcohol Review 2012; 31:194-7.
  • Lee N, Carter A, Owen N, Hall WD. The neurobiology of overeating: Treating overweight individuals should make use of neuroscience research, but not at the expense of population approaches to diet and lifestyle (Science and Society). EMBO Reports (European Molecular Biology Organization) 2012; 13:785-90.
  • Douglas H, Hammill J, Russell E, Hall WD. Judicial views of foetal alcohol spectrum disorder in Queensland’s criminal justice system. Journal of Judicial Administration 2012; 21:178-88.
  • Degenhardt L, Hall WD. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379:55-70.
  • Gartner C, Hall WD, Borland R. How should we regulate smokeless tobacco products and e-cigarettes? (Perspectives). Medical Journal of Australia 2012; 197:611-12.
  • Hunter EM, Gynther BD, Anderson CJ, Onnis LA, Nelson JR, Hall WD, Baune BT, Groves AR. Psychosis in Indigenous populations of Cape York and the Torres Strait. Medical Journal of Australia 2012; 196:133-5.
  • Haynes AS, Derrick GE, Redman S, Hall WD, Gillespie JA, Chapman S, Sturk H. Identifying trustworthy experts: How do policymakers find and assess public health researchers worth consulting or collaborating with? PLoS ONE (Public Library of Science) 2012; 7:e32665.
  • Leung J, Gartner C, Hall WD, Lucke J, Dobson A. A longitudinal study of the bi-directional relationship between tobacco smoking and psychological distress in a community sample of young Australian women. Psychological Medicine 2012; 42:1273-82.
  • Douglas H, Hammil J, Russell A, Hall WD. The importance of foetal alcohol spectrum disorder for criminal law practice: Views of Queensland criminal lawyers. Queensland Lawyer 2012; 32:153-64.
  • Teesson M, Farrugia P, Mills K, Hall WD, Baillie A. Alcohol, tobacco, and prescription drugs: The relationship with illicit drugs in the treatment of substance users. Substance Use & Misuse 2012; 47:963-71.
  • Gartner CE, Hall WD. Is the socioeconomic gap in childhood exposure to secondhand smoke widening or narrowing? Tobacco Control 2012; 10.1136/tobaccocontrol-2011-050297:March 30.
  • Prichard J, Lai FY, Kirkbride P, Bruno R, Ort C, Carter S, Hall WD, Gartner C, Thai P, Mueller J. Measuring drug use patterns in Queensland through wastewater analysis. Trends & Issues in Crime and Criminal Justice 2012; 442:8p.
  • Vos T, Flaxman A, Naghavi M, Lozano R, Michaud C, ..., Hall WD, ..., Lopez A, Murray C. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2163-96.
  • Murray C, Vos T, Lozano R, Naghavi M, Flaxman A, ..., Hall WD, ..., Lopez A. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-223.
  • Lim S, Vos T, Flaxman A, Danaei G, Shibuya K, ..., Hall WD, ..., Lopez A, Murray C, Ezzati M. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224-60.
  • Degenhardt L, Singleton J, Calabria B, McLaren J, Kerr T, Mehta S, Kirk G, Hall WD. Mortality among cocaine users: A systematic review of cohort studies. Drug and Alcohol Dependence 2011; 117:88-95.
  • Randall D, Degenhardt L, Vajdic C, Burns L, Hall WD, Law M, Butler T. Increasing cancer mortality among opioid-dependent persons in Australia: A new public health challenge for a disadvantaged population. Australian and New Zealand Journal of Public Health 2011; 35:220-25.
  • Mathews R, Hall WD, Vos T, Patton G, Degenhardt L. What are the major drivers of prevalent disability burden in young Australians? Medical Journal of Australia 2011; 194:232-35.
  • Hollingworth S, Rush A, Hall WD, Eadie M. Utilization of anti-Parkinson drugs in Australia: 1995-2009. Pharmacoepidemiology and Drug Safety 2011; 20:450-56.
  • Hall WD, Fischer B, Lenton S, Reuter P, Room R. Making space for cannabis policy experiments. Addiction 2011; 106:1192-93.
  • Fischer B, Jeffries V, Hall WD, Room R, Goldner E, Rehm J. Lower Risk Cannabis Use Guidelines for Canada (LRCUG): A narrative review of evidence and recommendations. Canadian Journal of Public Health 2011; 102:324-27.
  • Hollingworth S, Lie D, Siskind D, Byrne G, Hall WD, Whiteford H. Psychiatric drug prescribing in elderly Australians: time for action. Australian and New Zealand Journal of Psychiatry 2011; 45:705-08.
  • Pham B, Hall WD, Hill P. Indirect evidence of the contribution of prenatal sex selection practices to the high sex ratio at birth in Vietnam. Journal of Population Research 2011; 28:293-99.
  • Ambermoon P, Carter A, Hall WD, Dissanayaka N, O'Sullivan J. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction 2011; 106:283-93.
  • Carter A, Hall WD. Proposals to trial deep brain stimulation to treat addiction are premature (Editorial). Addiction 2011; 106:235-37.
  • Hall WD, Lucke JC. Untested assumptions about putative neuroenhancement. Addiction 2011; 106:1190-91.
  • Martire KA, Mattick RP, Doran CM, Hall WD. Cigarette tax and public health: What are the implications of financially stressed smokers for the effects of price increases on smoking prevalence? Addiction 2011; 106:622-30.
  • Lucke JC, Bell S, Partridge B, Hall WD. Deflating the neuroenhancement bubble. American Journal of Bioethics - Neuroscience 2011; 2:38-43,
  • Leung J, Gartner C, Dobson A, Lucke J, Hall WD. Psychological distress is associated with tobacco smoking and quitting behaviour in the Australian population: Evidence from national cross-sectional surveys. Australian and New Zealand Journal of Psychiatry 2011; 45:170-78.
  • Hall WD, Degenhardt L. Cannabis and the increased incidence and persistence of psychosis (Editorial). British Medical Journal 2011; 342:511-12.
  • Hall WD, Gartner C. Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Current Opinion in Psychiatry 2011; 24:191-96.
  • Degenhardt L, Bucello C, Calabria B, Nelson P, Roberts A, Hall WD, Lynskey M, Wiessing L. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug and Alcohol Dependence 2011; 117:85-101.
  • Lucke J, Bell S, Partridge B, Hall WD. Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals (Science and Society: Outlook). EMBO Reports (European Molecular Biology Organization) 2011; 12:197-201.
  • Hall WD, Carter A. Is deep brain stimulation a prospective cure for addiction? F1000 Medicine Reports 2011; 3:10.3410/M3-4.
  • Partridge B, Lucke J, Bartlett H, Hall WD. Public attitudes towards human life extension by intervening in ageing. Journal of Aging Studies 2011; 25:73-83.
  • Prichard J, Ort C, Bruno R, Gartner C, Kirkbride P, Hall WD, Lai FY, Carter S, Thai P, Mueller J, Salina A. Developing a method for site-specific wastewater analysis: Implications for prisons and other agencies with an interest in illicit drug use. Journal of Law, Information and Science 2011; 20:15-27.
  • Hall WD, Chikritzhs T. The Australian alcopops tax revisited (Comment). Lancet 2011; 377:1136-37.
  • Hall WD, Farrell M. Minimising the misuse of oxycodone and other pharmaceutical opioids in Australia (Editorial). Medical Journal of Australia 2011; 195:248-49.
  • Mathews R, Hall WD, Gartner C. Depression and psychological distress in tobacco smokers and people with cannabis dependence in the National Survey of Mental Health and Wellbeing. Medical Journal of Australia 2011; 195:S12-15.
  • Haynes AS, Gillespie JA, Derrick GE, Hall WD, Redman S, Chapman S, Sturk H. Galvanizers, guides, champions, and shields: the many ways that policymakers use public health researchers. Milbank Quarterly 2011; 89:564-98.
  • Collins P, Patel V, Joestl S, March D, Insel T, ..., Hall WD, ..., Walport M. Grand challenges in global mental health: A consortium of researchers announces here research priorities for improving the lives of peaople with mental illness around the world, and calls for urgent action and investment (Comment). Nature 2011; 475:27-30.
  • Boot B, Partridge B, Hall WD. Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people. Neurocase 2011; 18:181-4.
  • Carter A, Ambermoon P, Hall WD. Drug-induced impulse control disorders: A prospectus for neuroethical analysis. Neuroethics 2011; 4:91-102.
  • Carter A, Bell E, Racine E, Hall WD. Ethical issues raised by proposals to treat addiction using deep brain stimulation. Neuroethics 2011; 4:129-42.
  • Derrick G, Haynes A, Chapman S, Hall WD. The association between four citation metrics and peer rankings of research influence of Australian researchers in six fields of public health. PLoS ONE (Public Library of Science) 2011; 6:e18521.
  • Partridge B, Bell S, Lucke JC, Yeates S, Hall WD. Smart drugs as common as coffee: Media hype about neuroenhancement. PLoS ONE (Public Library of Science) 2011; 6:e28416.
  • Haynes AS, Derrick GE, Chapman S, Redman S, Hall WD, Gillespie J, Sturk H. From our world to the real world: Exploring the views and behaviour of policy-influential Australian public health researchers. Social Science & Medicine 2011; 72:1047-55.
  • Lai FY, Ort C, Gartner C, Carter S, Prichard J, Kirkbride P, Bruno R, Hall WD, Eaglesham G, Mueller JF. Refining the estimation of illicit drug consumptions from wastewater analysis: Co-analysis of prescription pharmaceuticals and uncertainty assessment. Water Research 2011; 45:4437-48.
  • Hall WD, Lucke J. The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addiction 2010; 105:2041-43.
  • Partridge B, Lucke J, Hall WD. Listening to public concerns about human life extension (Outlook). EMBO Reports (European Molecular Biology Organization) 2010; 11:735-37.
  • Lucke J, Herbert D, Partridge B, Hall WD. Anticipating the use of life extension technologies: Possible pointers from the adoption of assisted reproductive technologies. EMBO Reports (European Molecular Biology Organization) 2010; 11:334-38.
  • Hall WD, Lucke J. Legally coerced treatment for drug using offenders: ethical and policy issues. Crime and Justice Bulletin (BOSCAR, NSW Bureau of Crime Statistics and Research) 2010; 144:12p.
  • McLaren J, Silins E, Hutchinson D, Mattick R, Hall WD. Assessing evidence for a causal link between cannabis and psychosis: A review of cohort studies. International Journal of Drug Policy 2010; 21:10-19.
  • Calabria B, Degenhardt L, Hall WD, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug and Alcohol Review 2010; 29:318-30.
  • Teesson M, Hall WD, Slade T, Mills K, Grove R, Mewton L, Baillie A, Haber P. Prevalence and correlates of DSM-IV alcohol abuse and dependence in Australia: Findings of the 2007 National Survey of Mental Health and Wellbeing. Addiction 2010; 105:2085-94.
  • Hollingworth S, Siskind D, Nissen L, Robinson M, Hall WD. Patterns of antipsychotic medication use in Australia, 2002-2007. Australian and New Zealand Journal of Psychiatry 2010; 44:372-77.
  • Strang J, Hall WD, Hickman M, Bird S. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): Analyses using OD4 index in England and Scotland. British Medical Journal 2010; 341:c4851.
  • Doran C, Hall WD, Shakeshaft A, Vos T, Cobiac L. Alcohol policy reform in Australia: What can we learn from the evidence? (For debate). Medical Journal of Australia 2010; 192:468-70.
  • Calabria B, Doran C, Vos T, Shakeshaft A, Hall WD. Epidemiology of alcohol-related burden of disease among Indigenous Australians. Australian and New Zealand Journal of Public Health 2010; 34:S47-51.
  • Calabria B, Degenhardt L, Briegleb C, Vos T, Hall WD, Lynskey M, Callaghan B, Rana U, McLaren J. Systematic review of prospective studies investigating remission from amphetamine, cannabis, cocaine or opioid dependence. Addictive Behaviors 2010; 35:741-49.
  • Hall WD, Mathews R, Morley K. Being more realistic about the public health impact of genomic medicine (Policy forum). PLoS Medicine (Public Library of Science) 2010; 7:e1000347.
  • Hall WD, Wallace A, Cobiac L, Doran C, Vos T. How can we reduce alcohol-related road crash deaths among young Australians? (For debate). Medical Journal of Australia 2010; 192:464-66.
  • Gartner C, Jimenez-Soto E, Borland R, O'Connor R, Hall WD. Are Australian smokers interested in using low-nitrosamine smokeless tobacco for harm reduction? Tobacco Control 2010; 19:451-56.
  • Mathews R, Hall WD, Gartner C. Is there evidence of 'hardening' among Australian smokers between 1997 and 2007? Analyses of the Australian National Surveys of Mental Health and Well-Being. Australian and New Zealand Journal of Psychiatry 2010; 44:1132-36.
  • Gartner C, Chapman S, Hall WD, Wakefield M. Why we need tobacco sales data for good tobacco control (Editorial). Medical Journal of Australia 2010; 192:3-4.
  • Roxburgh A, Hall WD, Degenhardt L, McLaren J, Black E, Copeland J, Mattick R. The epidemiology of cannabis use and cannabis-related harm in Australia, 1993-2007. Addiction 2010; 105:1071-79.
  • Hall WD. What are the policy lessons of National Alcohol Prohibition in the United States, 1920-1933? (Addiction history). Addiction 2010; 105:1164-73.
  • Chikritzhs T, Allsop S, Moodie A, Hall WD. Per capita alcohol consumption in Australia: Will the real trend please step forward? Medical Journal of Australia 2010; 193:594-97.
  • Gartner C, Hall WD. Smokeless tobacco products: Unrecognised regulatory and policy opportunities (Editorial). Drug and Alcohol Review 2010; 29:119-20.
  • Macdonald S, Hall WD, Roman P, Stockwell T, Coghlan M, Nesvaag S. Testing for cannabis in the work-place: A review of the evidence. Addiction 2010; 105:408-16.
  • Smith A, Tett S, Hall WD. The contribution of injecting drug users in Sydney, Melbourne and Brisbane to rising benzodiazepine use in Australia, 2000 to 2006. Australian and New Zealand Journal of Public Health 2010; 34:315-19.
  • Hall WD. What would evidence-informed drug policies look like? (Editorial). Addiction 2010; 105:1135-36.
  • Liberman J, O'Brien M, Hall WD, Hill D. Ending inequities in access to effective pain relief? (Commentary on 'Providing paediatric palliative care in Kenya'). Lancet 2010; 376:856-57.
  • Freeman B, Gartner C, Hall WD, Chapman S. Forecasting future tobacco control policy: Where to next? Australian and New Zealand Journal of Public Health 2010; 34:447-50.
  • Pham B, Rao C, Adair T, Hill P, Hall WD. Assessing the quality of data for analysing the sex ratio at birth in Viet Nam. Asian Population Studies 2010; 6:263-87.
  • Hall WD, Fischer B. Harm reduction policies for cannabis. In: Rhodes T, Hedrich D, eds. Harm reduction: Evidence, impacts and challenges EMCDDA Scientific Monograph. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2010: 235-51.
  • Gartner C, Hall WD, McNeill A. Harm reduction policies for tobacco. In: Rhodes T, Hedrich D, eds. Harm reduction: Evidence, impacts and challenges EMCDDA Scientific Monograph. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2010: 255-73.
  • Partridge B, Lucke J, Bartlett H, Hall WD. Ethical, social, and personal implications of extended human lifespan identified by members of the public. Rejuvenation Research 2009; 12:351-57.
  • Underwood M, Bartlett H, Partridge B, Lucke J, Hall WD. Community perceptions on the significant extension of life: An exploratory study among urban adults in Brisbane, Australia. Social Science & Medicine 2009; 68:496-503.
  • Lucke J, Diedrichs P, Partridge B, Hall WD. Anticipating the anti-ageing pill: Lessons from the history of the oral contraceptive pill and hormone replacement therapy. EMBO Reports (European Molecular Biology Organization) 2009; 10:108-13.
  • Partridge B, Underwood M, Lucke J, Bartlett H, Hall WD. Ethical concerns in the community about technologies to extend human life span (Invited target article). American Journal of Bioethics 2009; 9:68-76.
  • Partridge B, Hall WD, Lucke J, Underwood M, Bartlett H. Mapping community concerns about radical extensions of human life expectancy. American Journal of Bioethics 2009; 9:W4-5.
  • Hall WD, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374:1383-91.
  • Degenhardt L, Randall D, Hall WD, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug and Alcohol Dependence 2009; 105:9-15.
  • Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, Degenhardt L. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: Patient characteristics and patterns and predictors of treatment retention. Addiction 2009; 104:1363-72.
  • Hall WD. The adverse health effects of cannabis use: What are they, and what are their implications for policy? International Journal of Drug Policy 2009; 20:458-66.
  • Hall WD, Gartner C. Supping with the Devil? The role of law in promoting tobacco harm reduction using low nitrosamine smokeless tobacco products. Public Health 2009; 123:287-91.
  • Gartner C, Barendregt J, Hall WD. Predicting the future prevalence of cigarette smoking in Australia: how low can we go and by when? Tobacco Control 2009; 18:183-89.
  • Singleton J, Degenhardt L, Hall WD, Zabransky T. Mortality among amphetamine users: A systematic review of cohort studies. Drug and Alcohol Dependence 2009; 105:1-8.
  • Hall WD, Degenhardt L, Teesson M. Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base. Addictive Behaviors 2009; 34:526-30.
  • Charlson F, Degenhardt L, McLaren J, Hall WD, Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiology and Drug Safety 2009; 18:93-103.
  • Gartner C, Barendregt J, Hall WD. Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction 2009; 104:118-26.
  • Degenhardt L, Whiteford H, Hall WD, Vos T. Estimating the burden of disease attributable to illicit drug use and mental disorders: What is 'Global Burden of Disease 2005' and why does it matter? Addiction 2009; 104:1466-71.
  • Hall WD, Lynskey M. The challenges in developing a rational cannabis policy. Current Opinion in Psychiatry 2009; 22:258-62.
  • Degenhardt L, Hall WD, Lynskey M, McGrath J, McLaren J, Calabria B, Whiteford H, Vos T. Should burden of disease estimates include cannabis use as a risk factor for psychosis?. PLoS Medicine (Public Library of Science) 2009; 6:e1000133.
  • Henderson S, Andrews G, Hall WD. State of the nation's mental health 2007. Australian and New Zealand Journal of Psychiatry 2009; 43:591-93.
  • Doran C, Shakeshaft A, Hall WD, Petrie D. Alcohol industry and government revenue derived from underage drinking by Australian adolescents, 2005. Addictive Behaviors 2009; 34:75-81.
  • Hall WD. Challenges in reducing cannabis-related harm in Australia. Drug and Alcohol Review 2009; 28:110-16.